Differences in Importance Attached to Drug Effects Between Patients With Type 2 Diabetes From the Netherlands and Turkey: A Preference Study von Roldan Munoz, Sonia, Postmus, Douwe, de Vries, Sieta T, Arnardottir, Arna H, Dolu, İlknur, Hillege, Hans, Mol, Peter G M

Volltext

Understanding drug preferences, different perspectives von Mol, Peter G. M., Arnardottir, Arna H., Straus, Sabine M. J., Graeff, Pieter A., Haaijer‐Ruskamp, Flora M., Quik, Elise H., Krabbe, Paul F. M., Denig, Petra

Volltext

Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study von Mol, Peter G. M., Arnardottir, Arna H., Motola, Domenico, Vrijlandt, Patrick J., Duijnhoven, Ruben G., Haaijer-Ruskamp, Flora M., de Graeff, Pieter A., Denig, Petra, Straus, Sabine M. J. M.

Volltext

Additional safety risk to exceptionally approved drugs in Europe? von Arnardottir, Arna H., Haaijer‐Ruskamp, Flora M., Straus, Sabine M. J., Eichler, Hans‐Georg, de Graeff, Pieter A., Mol, Peter G. M.

Volltext

Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class: An Analysis of European Public Assessment Reports von Arnardottir, Arna H., Haaijer-Ruskamp, Flora M., Straus, Sabine M. J., de Graeff, Pieter A., Mol, Peter G. M.

Volltext

Effect of Safety Issues with HIV Drugs on the Approval Process of Other Drugs in the Same Class von Arnardottir, Arna H, Haaijer-Ruskamp, Flora M, Straus, Sabine MJ, de Graeff, Pieter A, Mol, Peter GM

Volltext